New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 16, 2012
21:40 EDTSBAC, LBTYA, CTRX, WDC, REGN, EQIX, ADI, VRSK, LMCA, DISCAStocks being added to the NASDAQ-100 Index in annual re-ranking
The NASDAQ OMX Group announced the results of the annual re-ranking of the NASDAQ-100 Index, which will become effective prior to market open on Monday, December 24. The following ten securities will be added to the Index: Analog Devices, Inc. (ADI), Catamaran Corporation (CTRX), Discovery Communications (DISCA), Equinix, (EQIX), Liberty Global (LBTYA), Liberty Media Corporation (LMCA), Regeneron Pharmaceuticals (REGN), SBA Communications Corporation (SBAC), Verisk Analytics(VRSK) and Western Digital Corporation (WDC).
News For ADI;CTRX;DISCA;EQIX;LBTYA;LMCA;REGN;SBAC;VRSK;WDC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
17:15 EDTEQIXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
10:34 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTLBTYAHigh option volume stocks
High option volume stocks: POST SFM GSVC HGG HUN PH JWN CAR ONTY LBTYA
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.
07:04 EDTWDCWestern Digital can reach $10+ EPS in fiscal 2017, says RBC Capital
Subscribe for More Information
May 14, 2015
11:06 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
08:22 EDTADIAnalog Devices volatility flat into Q2 and outlook
Subscribe for More Information
May 13, 2015
12:42 EDTSBACAnalyst bullish on tower companies after meeting with American Tower
American Tower's (AMT) outlook has improved, and it should report strong 2016 results, research firm Pacific Crest wrote in a note to investors earlier today. American Tower owns towers used by cell phone carriers. WHAT'S NEW: After hosting a non-deal roadshow with American Tower, Pacific Crest analyst Michael Bowen said he had an "increasingly positive outlook" on the company in particular and the cell phone tower sector in general. Carrier tower applications rose last quarter, versus the second half of 2014, Bowen quoted American Tower and its peers as saying. This increase appears to bode well for the sector's performance in the second half of 2015 and 2016, according to Bowen, who expects American Tower to have strong 2016 results. The analyst predicts that American Tower's adjusted funds from operations, or AFFO, will increase about 9% in 2015 and 10.6% in 2016. However, the company estimated that its AFFO growth "could approach" mid-teen percentage levels if it decides not to acquire any more towers, according to Bowen. Additionally, American Tower reported that it believes it can eventually more than double the nearly 18,000 towers it owns in Brazil, Bowen reported. The analyst recommended that investors buy the stock. PRICE ACTION: In early afternoon trading, American Tower was flat at $93.56. Other tower owners were also little changed, as Crown Castle (CCI) was flat at $83, and SBA Communications (SBAC) added 0.7% to $116.21.
11:22 EDTCTRXOptions with increasing implied volatility
Subscribe for More Information
07:16 EDTDISCAMoffett Nathanson to hold a summit
Subscribe for More Information
May 12, 2015
10:28 EDTCTRXOptions with increasing implied volatility: YELP HUM LULU CTRX
Subscribe for More Information
10:01 EDTWDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:31 EDTDISCAApple likely to launch TV video service this year, says Pacific Crest
Subscribe for More Information
07:05 EDTWDCWestern Digital initiated with a Buy at Benchmark Co.
Target $117.
06:41 EDTDISCATV networks touting digital, targeting technologies to marketers, NY Times says
Subscribe for More Information
May 11, 2015
09:49 EDTEQIXInterXion could become takeover target, Ben Harrington says
Subscribe for More Information
08:24 EDTEQIXEquinix and Global Capacity announce collaboration
Subscribe for More Information
07:40 EDTCTRXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
06:33 EDTDISCATV networks worried amid tough competition from digital outlets, NY Times says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use